AI & Real-World Data: A Perfect Union

Posted by Arun Shastri on Mon, Jan 27, 2020

This blog post is the seventh in a series on the impact that AI will have on different business aspects of pharma.

Real world data (RWD) is as old as data itself. It was relatively useless, however, until it was digitized. And then once it was digitized, we struggled to analyze so much data at scale with any kind of efficiency.

Enter our ability to store and analyze large volumes of data and advancements in data science, algorithms and technology. With the help of AI, it’s now possible to truly leverage RWD and begin to understand patient populations in holistic ways that have so far eluded pharmaceutical companies. It’s accelerating the use of evidence across healthcare to support the focus on patient health outcomes.


>
Read More

AI & Clinical Trials: Poised for Disruption

Posted by Arun Shastri on Wed, Sep 11, 2019

This blog post is the third in a series on the impact that AI will have on different business aspects of pharma.

We always tell our clients to start small with AI. As Pratap Khedkar shared in my first interview, it’s important to start with clear, specific use cases. For some aspects of the business, it may take some time to carefully consider what these specific use cases are and what opportunities AI can create. Clinical trials present no such difficulties. The opportunities to improve efficiencies are numerous and clear, and AI has begun to make an impact. The industry is aware of the inefficiencies that abound in clinical trial design and execution and is eager to solve them.


>
Read More

Collaboration in Clinical Operations: Three Takeaways From SCOPE 2018

Posted by Qin Ye on Fri, Mar 02, 2018

Abhay Jha and Venkat Sethuraman co-wrote this blog post with Qin Ye.

More people than ever before attended the ninth-annual Summit for Clinical Ops Executives (SCOPE)—a testament to the growing importance of innovation within clinical development. Attendees from across life sciences gathered in Orlando Feb. 12-15 to discuss clinical development challenges and solutions, and to network with peers and partners.


>
Read More

How Pharma Companies Are Engaging Patients as R&D Partners

Posted by Kristyn Feldman on Wed, Nov 08, 2017

Lisa Bance co-wrote this blog post with Kristyn Feldman.

This is the final post in a four-part series examining patient centricity within R&D.

To achieve true patient centricity in drug development, pharmaceutical companies need to follow four main principles: gain empathy for patients, uncover and meet patient needs, connect with patients and, finally, engage patients. By asking for and incorporating trial participant input at every level of R&D, the pharmaceutical industry can start to look at patients as true partners.


>
Read More

How Technology and Analytics Are Helping Big Pharma Improve Patient Engagement in R&D

Posted by Kristyn Feldman on Wed, Nov 01, 2017

Lisa Bance co-wrote this blog post with Kristyn Feldman.

This is the third post in a four-part series examining patient centricity within R&D.

As drug development continues to grow more expensive and complex, and as patients expect to be more involved and empowered throughout the healthcare system, pharmaceutical companies are seeing the value in partnering with patients throughout the R&D process. The journey begins with building an understanding of and empathy for today’s patients, and then uncovering and meeting their needs. The third step is to hone in on how you connect with patients to increase the effectiveness of your communications.


>
Read More